Editorial


A new subtyping model for residual invasive disease after cisplatin-based neoadjuvant chemotherapy for muscle invasive bladder cancer

Archana Agarwal, Guru Sonpavde

Abstract

Muscle invasive bladder cancer (MIBC) is an aggressive malignancy and half of the patients develop metastatic disease within 2 years, which is generally incurable and leads to early mortality (1). Based on prospective randomized trials, MIBC is treated with cisplatin-based neoadjuvant chemotherapy (NAC) followed by radical cystectomy (RC) (2-4).

Download Citation